**Abstract**

Recently, the glutamatergic hypofunction hypothesis of schizophrenia has been proposed. D-cycloserine is a partial N-methyl-D-aspartate (NMDA) receptor agonist, which has been proposed as a means of treating the negative symptoms in schizophrenia. The objective purpose of the present study was to examine structural and functional brain alterations in schizophrenia patients treated with D-cycloserine using voxel-based morphometry (VBM) and resting-state functional connectivity analysis. Eight patients underwent an 18-week double-blind randomized crossover-design clinical trial. Whole brain structural and resting-state functional magnetic resonance imaging, performed at baseline and after 6 weeks of D-cycloserine or placebo, were compared at each time point. Gray matter volume (GMV) was investigated by VBM. Once D-cycloserine-mediated structural alterations were found, resting-state functional connectivity analysis was used to examine the correlations between regions of interest which has altered by D-cycloserine treatment and other regions. Compared to baseline or placebo treatment, D-cycloserine treatment resulted in increased GMV in the left hippocampus. This region have been proposed to be involved in negative symptoms. We also found decreased connectivity of the left superior temporal gyrus with the structural increased region after D-cycloserine administration. This connectivity change has been proposed to be involved in exacerbated hallucinations in schizophrenia. Our study suggests the possibility that D-cycloserine could be considered as a therapeutic drug targeting negative symptoms in schizophrenia. However, further investigation are required to ensure safe and efficient treatment. This is the first study revealing the pharmacological effect of D-cycloserine from the viewpoint of brain structure and functional connectivity.
